OKM Co., Ltd – Japanese Low-Fat Okara to Launch in the US

An exciting, new addition to the low-fat, low-carb niche is set to be released to the American health food market in 2021.

Fujioka City, Feb. 05, 2021 (GLOBE NEWSWIRE) — Okumura Engineering Corp (OKM) is ready to unveil Okara curry flakes: an enticing option for health-conscious curry lovers. Okara is gluten-free, vegan, low in trans-fats, and free of sugar, chemicals, artificial colors and flavors, and preservatives.

The company has adopted a method to utilize Okara; the soy pulp that is often left behind as a result of filtering pureed soybeans in the production of soy milk and tofu. 

Over 600,000 tons of Okara are currently generated in Japan but has traditionally been disposed of as it is challenging to manage due to its high moisture content contributing to spoilage and easy deterioration.

As Okara is highly nutritious and contains many essential nutrients for the human body, OKM has now developed advances in its processes to dry out the Okara pulp and ground it into a powder. It not only increases its shelf life but packs all its nutritional content into a condensed form. 

The resultant Okara powder is gluten-free, vegan, low carb, and contains around 60% dietary fibers and 20% protein. It is also extremely nutritious, loaded with calcium, folic acid, isoflavones, and has a low GI (Glycemic Index).

“It is an enticing option for the health-conscious curry lover. Our curry flakes will be attractive to those that are vegan and gluten-free, as well as being low in carbs,” commented OKM’s CEO Miho Sakurai.

“Anything with wheat or rice flour from noodles to bread can be made gluten-free by substituting it with our Okara powder. It provides the protein and calcium that tends to be lacking in vegan diets, while also being low in the carbohydrates that gluten-free diets tend to be high in.”

With its host of benefits — plentiful dietary fibers improving digestive health, and soybean oligosaccharides stimulating the growth of beneficial microbes in the gut — Okara powder is also highly recommended by medical experts.

Ready and available for the American market, OKM’s curry powder has been made with brown rice flour, Okara, white sorghum and rice flour. Easy to dissolve and be used as a seasoning, the curry flakes have been made with more than 18 kinds of spices, ensuring the authentic flavor will please even the most demanding curry connoisseurs. 

The product is sugar-free, with pureed dates having been used as a sweetener, while coconut oil has been used to lower trans-fat intake. The product is also free of palm oil.

The Fujioka, Gunma-based company already utilizes Okara powder in a range of various processed foods. In addition, you can easily take the nutrition of Okara by sprinkling it on yogurt, soup, and even ice cream.

View OKM’s website: http://okara-la-life.com.email [email protected]

For inquiries from customers and the press regarding this release, please contact:

Global brand Inc. / JAPAN

+81-80-9644-4222

Website: http://globalbrand.co.jp/usa/

Facebook: https://web.facebook.com/Global-Brand-102715218383091?_rdc=1&_rdr

Instagram: https://instagram.com/global.brand_

Attachment



Media Company: Global Brand, Inc.
Media Name: Takahiro Yamada 
Media Phone: +81-(0)52-686-2095. 
Media Email: [email protected]

Genworth MI Canada Inc. Announces Name Change to Sagen MI Canada Inc.

Canada NewsWire

TORONTO, Feb. 5, 2021 /CNW/ – Sagen MI Canada Inc. (formerly Genworth MI Canada Inc.) (the “Company“) (TSX: MIC), is pleased to announce that the Company has amended its articles in accordance with the Canada Business Corporations Act and, effective today, has changed its name to Sagen MI Canada Inc. (the “Name Change“). The Company’s common shares are expected to begin trading on the Toronto Stock Exchange (“TSX“) under the new name at market open on or around February 9, 2021. The Company’s common shares will continue to trade under the TSX ticker symbol “MIC”.

At the special meeting of the Company’s shareholders held on December 22, 2020, shareholders passed a special resolution authorizing an amendment to the Company’s articles to effect the Name Change. The articles of amendment effecting the Name Change are available on the Company’s SEDAR profile at www.sedar.com.

No action is required by shareholders in connection with the Name Change, and no change has been made to the Company’s share capital. The Company encourages any shareholder with questions to contact their broker or agent.

About Sagen MI Canada Inc. 

Sagen MI Canada Inc. (TSX: MIC), operating through its subsidiary, Genworth Financial Mortgage Insurance Company Canada doing business as SagenTM, is the largest private sector residential mortgage insurer in Canada. The Company provides mortgage default insurance to Canadian residential mortgage lenders, making homeownership more accessible to first-time homebuyers. The Company differentiates itself through customer service excellence, innovative processing technology, and a robust risk management framework. For more than two decades, the Company has supported the housing market by providing thought leadership and a focus on the safety and soundness of the mortgage finance system. As at December 31st, 2020, the Company had $7.5 billion total assets and $3.9 billion shareholders’ equity. Find out more at www.sagen.ca.


Contact Information

:

Investors – Aaron Williams, 905-287-5504 [email protected]
Media Susan Carter, 905-287-5520  [email protected]

Caution regarding forward-looking information and statements

Certain statements made in this news release contain forward-looking information within the meaning of applicable securities laws (“forward-looking statements”). When used in this news release, the words “may”, “would”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “seek”, “propose”, “estimate”, “expect”, and similar expressions, as they relate to the Company are intended to identify forward-looking statements. Specific forward-looking statements in this document include, but are not limited to, the statement regarding the date on which the Company’s common shares are expected to begin trading on the TSX under its new name.

The forward-looking statements contained herein are based on certain factors and assumptions, certain of which appear proximate to the applicable forward-looking statements contained herein. Inherent in the forward-looking statements are known and unknown risks, uncertainties and other factors beyond the Company’s ability to control or predict, that may cause the actual results, performance or achievements of the Company, or developments in the Company’s business or in its industry, to differ materially from the anticipated results, performance, achievements or developments expressed or implied by such forward-looking statements. Actual results or developments may differ materially from those contemplated by the forward-looking statements.

The Company’s actual results and performance could differ materially from those anticipated in these forward-looking statements as a result of both known and unknown risks, including risks that the Company’s common shares do not begin trading on the TSX under its new name by the date that is expected.

This is not an exhaustive list of the factors that may affect any of the Company’s forward-looking statements. Some of these and other factors are discussed in more detail in the Company’s Annual Information Form (the “AIF“) dated March 11th, 2020. Investors and others should carefully consider these and other factors and not place undue reliance on the forward-looking statements. Further information regarding these and other risk factors is included in the Company’s public filings with provincial and territorial securities regulatory authorities (including the AIF) and can be found on SEDAR and available at www.sedar.com. The forward-looking statements contained in this news release represent the Company’s views only as of the date hereof. Forward-looking statements contained in this news release are based on management’s current plans, estimates, projections, beliefs and opinions and the assumptions related to these plans, estimates, projections, beliefs and opinions may change, and are presented for the purpose of assisting the Company’s security holders in understanding management’s current views regarding those future outcomes and may not be appropriate for other purposes. While the Company anticipates that subsequent events and developments may cause the Company’s views to change, the Company does not undertake to update any forward-looking statements, except to the extent required by applicable securities laws.

___________________________

Sagen is a trademark owned by Sagen MI Canada Inc.

SOURCE Genworth MI Canada

Perspecta announces financial results for third quarter of fiscal year 2021

– Revenue of $1.13 billion

– Diluted earnings per share of $0.19; adjusted diluted earnings per share of $0.56

– Operating cash flow of $117 million

– Bookings of $0.9 billion (Q3 book-to-bill ratio of 0.8x; trailing-twelve-month book-to-bill ratio excluding NGEN SMIT impact of 1.2x)

PR Newswire

CHANTILLY, Va., Feb. 5, 2021 /PRNewswire/ — Perspecta Inc. (NYSE:PRSP), a leading U.S. government services provider, today announced financial results for the third quarter of fiscal year 2021, which ended January 1, 2021.

As previously announced on January 27, 2021, Perspecta entered into a definitive merger agreement to be acquired by Peraton, a portfolio company of Veritas Capital Fund Management, L.L.C. Under the terms of the merger agreement, Perspecta stockholders will receive $29.35 per share in cash. The merger is subject to customary conditions, including approval by Perspecta stockholders as well as the receipt of regulatory approvals and other customary closing conditions. The transaction is expected to close in the first half of calendar year 2021.

Summary operating results (unaudited)


Fiscal Quarter Ended

(in millions, except margin and per share amounts)


January 1, 2021


December 31, 2019

Revenue

$

1,134

$

1,126

Income before taxes

$

45

$

75

Operating margin

4.0

%

6.7

%

Net income

$

31

$

53

Diluted earnings per share (EPS)

$

0.19

$

0.33

Non-GAAP Measures*:

Adjusted Net Income

$

90

$

90

Adjusted EBITDA

$

181

$

195

Adjusted EBITDA Margin

16.0

%

17.3

%

Adjusted Diluted EPS

$

0.56

$

0.55

* Adjusted Net Income, Adjusted EBITDA, Adjusted EBITDA Margin and Adjusted Diluted EPS are non-GAAP financial measures. Non-GAAP financial measures should be considered in addition to, but not as a substitute for, the information provided in accordance with GAAP. See Selected Financial Data and Reconciliation of Non-GAAP Financial Measures at the end of this press release for more information.

The tables in Selected Financial Data and Reconciliation of Non-GAAP Financial Measures at the end of this press release provide all appropriate reconciliations from adjusted results to GAAP.

Revenue for the quarter was $1.13 billion, up 1% compared to the third quarter of fiscal year 2020, and down 1% compared to the second quarter of fiscal year 2021. The year-over-year increase in revenue was due to growth on existing programs partially offset by the COVID-19 impact of approximately $19 million in the third quarter of fiscal year 2021. Excluding the impact of the COVID-19 pandemic, revenue for the quarter grew 2% year-over-year. 

Income before taxes for the third quarter of fiscal year 2021 was $45 million, which was down 40% compared to the third quarter of fiscal year 2020. Operating margin decreased from 6.7% to 4.0% year-over-year. Net income was $31 million, or $0.19 per diluted share.

Adjusted net income was $90 million for the third quarter of fiscal year 2021, which was flat year-over-year. Adjusted EBITDA was $181 million for the third quarter of fiscal year 2021, down 7% compared to adjusted EBITDA for the third quarter of fiscal year 2020. The as-expected year-over-year decrease in profitability was primarily due to lower asset intensity, an increased mix of cost-reimbursable programs and a $3 million COVID-19 impact. Adjusted diluted EPS for the third quarter of fiscal year 2021 was $0.56, up 2% compared to adjusted diluted EPS for the third quarter of fiscal year 2020.

Segment operating results (unaudited)

For the fiscal quarter ended January 1, 2021, Defense and Intelligence segment revenue of $795 million decreased by 2% compared to the segment’s revenue from the third quarter of fiscal year 2020, primarily due to lower volume, including revenue lost as a result of COVID-19. Civilian and Health Care segment revenue of $339 million increased by 8% compared to the segment’s revenue from the comparable period of the prior year due to the continued ramp up of key new programs.

Defense and Intelligence adjusted segment profit margin for the third quarter of fiscal year 2021 decreased to 13.2% from 14.4% in the third quarter of fiscal year 2020. Civilian and Health Care adjusted segment profit margin for the third quarter of fiscal year 2021 decreased to 12.7% from 12.8% in the third quarter of fiscal year 2020.

Cash management and capital deployment

Perspecta generated $117 million of net cash provided by operating activities, used $5 million in investing activities, and used $101 million in financing activities in the third quarter of fiscal year 2021. Quarterly free cash flow was $93 million, or 103% of adjusted net income, and was reduced by $15 million (or approximately 17% of adjusted net income) of restructuring, separation, transaction, and integration-related costs. During the third quarter of fiscal year 2021, Perspecta used $72 million to make debt repayments and returned $11 million to shareholders in the form of its regular quarterly cash dividend program.

At quarter end, Perspecta had $224 million in cash and cash equivalents, $750 million of undrawn capacity in its revolving credit facility, and $2.4 billion in total debt, including $191 million in finance lease obligations. On February 3, 2021, the Perspecta Board of Directors declared that Perspecta will pay a cash dividend of $0.07 per share on April 15, 2021 to Perspecta shareholders of record at the close of business on March 3, 2021.

Contract awards

Contract awards (bookings) totaled $0.9 billion in the third quarter of fiscal year 2021, representing a book-to-bill ratio of 0.8x. Included in the quarterly bookings were the following single-award prime contracts:

  • Space Development Agency (SDA) systems engineering and integration program work: Perspecta will deliver systems engineering and integration support for SDA’s initial satellite constellation known as Tranche 0, a system designed to demonstrate the initial capabilities of the National Defense Space Architecture (NDSA). Under the terms of the agreement, Perspecta engineers and architects will develop infrastructure to ensure the NDSA Transport Layer, Tracking Layer and ground segment operate in unison to support warfighter mission scenarios and experiments. The single award, indefinite delivery/indefinite quantity (ID/IQ) contract, which represents new work for the company, has a ceiling of $112 million and an ordering period of five years.
  • Next Generation Enterprise Services Contract Extension from the U.S. Navy: Perspecta was awarded an extension of the Next Generation Enterprise Network (NGEN) contract from the U.S. Department of the Navy with a maximum ceiling value of $797 million, if all options are exercised, for continued delivery of enterprise IT services. The ID/IQ contract includes an extension for six months of support, from January 1, 2021 to June 30, 2021, and three one-month options beyond that timeframe.

Perspecta’s backlog of signed business orders at the end of the third quarter of fiscal year 2021 was $13.6 billion; funded backlog at the end of the third quarter was $1.7 billion.

The fourth quarter of fiscal year 2020 marked the beginning of the COVID-19 pandemic in the United States, and the pandemic has continued through the third quarter of fiscal year 2021. Due to the mission-critical nature of the majority of our business, substantially all of the services we provide to our government customers have been considered essential services, which has allowed them to continue, and the company has maintained its workforce at near full capacity. For the fiscal quarter ended January 1, 2021, the overall impact of the COVID-19 pandemic on our results of operations was approximately $19 million lower revenue, $3 million lower adjusted EBITDA and a year-to-date liquidity benefit of $57 million due to a deferral of payroll tax payments afforded by the Coronavirus Aid, Relief and Economic Security Act. We continue to assess further possible implications to our business, supply chain and customers, and to take actions in an effort to mitigate adverse consequences.

About Perspecta Inc.

At Perspecta, we question, we seek and we solve. Perspecta brings a diverse set of capabilities to our U.S. government customers in defense, intelligence, civilian, health care and state and local markets. Our 280+ issued, licensed and pending patents are more than just pieces of paper, they tell the story of our innovation. With offerings in mission services, digital transformation and enterprise operations, our team of nearly 14,000 engineers, analysts, investigators and architects work tirelessly to not only execute the mission, but build and support the backbone that enables it. Perspecta was formed to take on big challenges. We are an engine for growth and success and we enable our customers to build a better nation. For more information about Perspecta, visit perspecta.com.

Forward-looking statements

All statements and assumptions in this press release that do not directly and exclusively relate to historical facts could be deemed “forward-looking statements.” Forward-looking statements are often identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “may,” “could,” “should,” “forecast,” “goal,” “intends,” “objective,” “plans,” “projects,” “strategy,” “target” and “will” and similar words and terms or variations of such. These statements represent current intentions, expectations, beliefs or projections, and no assurance can be given that the results described in such statements will be achieved. Forward-looking statements include, among other things, statements with respect to the expected timing of the closing of the merger with Peraton and our financial condition, results of operations, cash flows, business strategies, prospects, guidance, share repurchases, dividend payments, contract value, revenue acceleration, profitability and revenue generation. Such statements are subject to numerous assumptions, risks, uncertainties and other factors that could cause actual results to differ materially from those described in such statements, many of which are outside of our control. Important factors that could cause actual results to differ materially from those described in forward-looking statements include, but are not limited to, (i) potential disruptions to our business caused by the proposed acquisition of us by Peraton, a portfolio company of Veritas Capital Fund Management, L.L.C.; (ii) failure to complete the merger with Peraton in a timely manner or at all; (iii) various risks related to health epidemics, pandemics and similar outbreaks, such as the COVID-19 pandemic, which may have material adverse effects on our business, financial position, results of operations and/or cash flows; (iv) any issue that compromises our relationships with the U.S. federal government, or any state or local governments, or damages our professional reputation; (v) changes in the U.S. federal, state and local governments’ spending and mission priorities that shift expenditures away from agencies or programs that we support; (vi) any delay in completion of the U.S. federal government’s budget process; (vii) failure to comply with numerous laws, regulations and rules, including regarding procurement, anti-bribery and organizational conflicts of interest; (viii) failure by us or our employees to obtain and maintain necessary security clearances or certifications; (ix) our ability to compete effectively in the competitive bidding process and delays, contract terminations or cancellations caused by competitors’ protests of major contract awards received by us; (x) our ability to accurately estimate or otherwise recover expenses, time and resources for our contracts; (xi) problems or delays in the development, delivery and transition of new products and services or the enhancement of existing products and services to meet customer needs and respond to emerging technological trends; (xii) failure of third parties to deliver on commitments under contracts with us; (xiii) misconduct or other improper activities from our employees or subcontractors; (xiv) delays, terminations, or cancellations of our major contract awards, including as a result of our competitors protesting such awards; (xv) failure of our internal control over financial reporting to detect fraud or other issues; (xvi) failure or disruptions to our systems, due to cyber-attack, service interruptions or other security threats; (xvii) failure to be awarded task orders under our indefinite delivery/indefinite quantity contracts; (xviii) changes in government procurement, contract or other practices or the adoption by the government of new laws, rules and regulations in a manner adverse to us; and (xix) uncertainty from the expected discontinuance of the London Interbank Offered Rate and transition to any other interest rate benchmark; as well as the matters described in the “Cautionary Statement Regarding Forward-Looking Statements” and “Risk Factors” sections of Perspecta’s Annual Report on Form 10-K for the fiscal year ended March 31, 2020, as may be updated or supplemented in our Quarterly Reports on Form 10-Q and our other filings with the Securities and Exchange Commission, which discuss these and other factors that could adversely affect our results. Readers are cautioned not to place undue reliance on such statements which speak only as of the date they are made. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.


Condensed Consolidated Statements of Operations

(preliminary and unaudited)


Fiscal Quarter Ended

(in millions, except per share amounts)


January 1, 2021


December 31, 2019

Revenue

$

1,134

$

1,126

Costs of services

906

863

Selling, general and administrative

57

77

Depreciation and amortization

93

92

Restructuring costs

2

Separation, transaction and integration-related costs

7

20

Interest expense, net

28

34

Other (income) expense, net

(4)

(35)

Total costs and expenses

1,089

1,051

Income before taxes

45

75

Income tax expense

14

22

Net income

$

31

$

53

Earnings per common share:

Basic

$

0.19

$

0.33

Diluted

$

0.19

$

0.33

 


Selected Condensed Consolidated Balance Sheets

(preliminary and unaudited)

(in millions)


January 1, 2021


March 31, 2020

ASSETS

Current assets:

Cash and cash equivalents

$

224

$

147

Receivables, net of allowance for doubtful accounts of $1 and $1

531

513

Other receivables

11

45

Prepaid expenses

63

81

Other current assets

69

101

Total current assets

898

887

Property and equipment, net of accumulated depreciation of $280 and $193

262

307

Goodwill

2,702

2,671

Intangible assets, net of accumulated amortization of $691 and $515

1,026

1,193

Other assets

314

347

Total assets

$

5,202

$

5,405

LIABILITIES and SHAREHOLDERS’ EQUITY

Current liabilities:

Current maturities of long-term debt

$

90

$

89

Current finance lease obligations

96

111

Current operating lease obligations

33

39

Accounts payable

191

218

Accrued payroll and related costs

203

142

Accrued expenses

363

385

Other current liabilities

96

73

Total current liabilities

1,072

1,057

Long-term debt, net of current maturities

2,123

2,283

Non-current finance lease obligations

95

136

Non-current operating lease obligations

126

129

Deferred tax liabilities

71

114

Other long-term liabilities

307

329

Total liabilities

3,794

4,048

Commitments and contingencies

Total shareholders’ equity

1,408

1,357

Total liabilities and shareholders’ equity

$

5,202

$

5,405

 


Condensed Consolidated Statements of Cash Flows

(preliminary and unaudited)


Fiscal Quarter Ended


Three Fiscal Quarters Ended

(in millions)


January 1,
2021


December 31,
2019


January 1,
2021


December 31,
2019

Cash flows from operating activities:

Net income

$

31

$

53

$

44

$

113

Adjustments to reconcile net (loss) income to net cash provided by operating activities:

Depreciation and amortization

93

92

285

283

Share-based compensation

10

6

27

21

Deferred income taxes

(31)

24

(48)

4

Loss (gain) on sale or disposal of assets, net

(33)

12

(23)

Other non-cash charges, net

1

(1)

12

3

Changes in assets and liabilities, net of effects of acquisitions:

Receivables, net

26

(1)

51

49

Prepaid expenses and other current assets

9

(8)

16

38

Accounts payable, accrued expenses and other current liabilities

(9)

(4)

28

(20)

Deferred revenue and advanced contract payments

(12)

(8)

1

(24)

Income taxes payable and liability

4

(4)

(3)

(6)

Other assets and liabilities, net

(5)

4

(12)

2

Net cash provided by operating activities

117

120

413

440

Cash flows from investing activities:

Payments for acquisitions, net of cash acquired

(53)

(265)

Proceeds from sale of assets

1

77

10

77

Purchases of property, equipment and software

(6)

(7)

(32)

(11)

Payments for outsourcing contract costs

(1)

(4)

Net cash used in investing activities

(5)

69

(75)

(203)

Cash flows from financing activities:

Principal payments on long-term debt

(72)

(24)

(124)

(69)

Payments of debt issuance costs

(3)

Proceeds from revolving credit facility

175

Payments on revolving credit facility

(125)

(50)

(125)

Payments on finance lease obligations

(18)

(33)

(85)

(110)

Repurchases of common stock

(14)

(46)

Repurchases of common stock to satisfy tax withholding obligations

(1)

(2)

(3)

(2)

Dividends paid

(11)

(10)

(32)

(28)

Proceeds from employee stock purchase plan

1

1

Net cash used in financing activities

(101)

(208)

(293)

(208)

Net change in cash and cash equivalents, including restricted

11

(19)

45

29

Cash and cash equivalents, including restricted, at beginning of period

255

147

221

99

Cash and cash equivalents, including restricted, at end of period

266

128

266

128

Less restricted cash and cash equivalents included in other current assets

42

59

42

59

Cash and cash equivalents at end of period

$

224

$

69

$

224

$

69

Selected Financial Data and Reconciliation of Non-GAAP Financial Measures

The following tables present selected financial data, including the reconciliation of non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP. Perspecta management believes that these non-GAAP financial measures provide useful additional information to investors regarding Perspecta’s results of operations as they provide another measure of Perspecta’s profitability and ability to service its debt and are considered important to financial analysts covering Perspecta’s industry.

These non-GAAP financial measures have limitations as an analytical tool and should not be considered in isolation or as a substitute for income from operations, net income, diluted EPS or any other measure of financial performance reported in accordance with GAAP. Perspecta’s non-GAAP measures may be calculated differently than similarly named measures reported by other companies. In addition, using non-GAAP measures may have limited value as they exclude certain items that may have a material impact on reported financial results and cash flows. When analyzing Perspecta’s performance, it is important to evaluate each adjustment in the reconciliation tables and use adjusted measures in addition to, and not as an alternative to, GAAP measures.

The tables below provide information about the estimated financial impact of the network component of the existing U.S. Navy NGEN Service Management, Integration, and Transport (SMIT) contract, for which we are under contract through June 30, 2021, and which includes the potential for three one-month options beyond that timeframe.


Revenue Excluding NGEN SMIT (Unaudited)


Fiscal Quarter Ended

(in millions)


January 1, 2021


December 31, 2019

Revenue

$

1,134

$

1,126

Less NGEN SMIT impact

221

221

Revenue excluding NGEN SMIT impact

$

913

$

905


Adjusted EBITDA, Net Income, and Diluted EPS (Unaudited)

Adjusted EBITDA excludes the following items: interest, income taxes, depreciation and amortization, restructuring, separation, transaction and integration-related costs, mark-to-market adjustments to the pension and other post-employment benefit programs, stock-based compensation, and other non-recurring items. There were no mark-to-market changes in either the current or year-ago quarterly periods. Adjusted net income and adjusted diluted EPS also exclude acquisition-related intangible amortization.


Fiscal Quarter Ended

(in millions, except margin)


January 1, 2021


December 31, 2019


Net income


$


31


$


53

Income tax expense

14

22

Interest expense, net

28

34

Depreciation and amortization

93

92


EBITDA


166


201

Restructuring costs

2

Separation, transaction and integration-related costs

7

20

Share-based compensation

10

6

Gain on sale of assets

(33)

Other

(4)

1


Adjusted EBITDA


181


195



Adjusted EBITDA margin (a)



16.0



%



17.3



%


NGEN SMIT EBITDA


34


29


Adjusted EBITDA, excluding NGEN SMIT (b)


147


166



Adjusted EBITDA margin, excluding NGEN SMIT (b)



16.1



%



18.3



%

Depreciation and amortization

(93)

(92)

Amortization of acquired intangibles

60

54

Interest expense, net

(28)

(34)


Adjusted earnings before taxes


120


123

Income tax expense (c)

30

33


Adjusted net income


90


90


Impact of NGEN SMIT (d)


24


21


Adjusted net income, excluding NGEN SMIT


$


66


$


69


Notes:

(a)

Adjusted EBITDA margin is calculated as the ratio of adjusted EBITDA to revenue for the fiscal quarters ended January 1, 2021 and December 31, 2019.

(b)

Adjusted EBITDA, excluding NGEN SMIT is defined as revenue less cost of services, selling, general and administrative and excludes certain operating expenses managed at the corporate level. These unallocated costs include certain corporate function costs, share-based compensation expense, amortization of acquired intangible assets, impairment charges, certain nonrecoverable restructuring costs, separation, transaction and integration-relate costs, net periodic benefit cost and gain or loss on sale of assets. Adjusted EBITDA margin, excluding NGEN SMIT is calculated as the ratio of adjusted EBITDA, excluding NGEN SMIT to revenue excluding NGEN SMIT for the fiscal quarters ended January 1, 2021 and December 31, 2019.

(c)

Represents income tax expense utilizing an adjusted effective tax rate that adjusts for non-GAAP measures including: transaction costs, integration costs, and tax add backs for non-deductible prior-merger goodwill amortization. Adjusted effective tax rates were 25% for the fiscal quarter ended January 1, 2021, and 27% for the fiscal quarter ended December 31, 2019.

(d)

Impact of NGEN SMIT is NGEN SMIT EBITDA less NGEN SMIT depreciation and income tax at the adjusted effective tax rates of 25% for the fiscal quarter ended January 1, 2021, and 27% for the fiscal quarter ended December 31, 2019.

 


Fiscal Quarter Ended

(in dollars)


January 1, 2021


December 31, 2019


Diluted EPS


$


0.19


$


0.33

Restructuring costs

0.01

Separation, transaction and integration-related costs

0.05

0.12

Share-based compensation

0.06

0.04

Gain on sale of assets

(0.20)

Amortization of acquired intangibles

0.37

0.33

Other

(0.02)

Tax impact related to non-GAAP adjustments

(0.10)

(0.07)


Adjusted diluted EPS


0.56


0.55


Impact of NGEN SMIT

(0.15)

(0.13)


Adjusted diluted EPS, excluding NGEN SMIT


$


0.41


$


0.42

Diluted weighted average common shares outstanding (in millions)

162.13

162.47


Free Cash Flow (Unaudited)

Perspecta defines free cash flow as net cash provided by operating activities less (i) purchases of property, equipment and software, (ii) payments on finance lease obligations, and (iii) the impact arising from the initial sale of accounts receivables under the Master Accounts Receivable Purchase Agreement.


Fiscal Quarter Ended

(in millions)


January 1, 2021


December 31, 2019

Net cash provided by operating activities

$

117

$

120

Purchases of property, equipment and software

(6)

(7)

Payments on finance lease obligations

(18)

(33)

Initial sale of qualifying receivables (a)

(17)

Free cash flow

$

93

$

63

Notes:

(a)

Represents the impact arising from the initial sale of accounts receivables under the Master Accounts Receivable Purchase Agreement during the fiscal quarter ended December 31, 2019.

The Company had $15 million and $35 million of payments for restructuring, separation, transaction and integration-related costs for the fiscal quarters ended January 1, 2021 and December 31, 2019, respectively.


Segment Operating Results (Unaudited)

Perspecta delivers IT, mission, and operations-related services across the U.S. federal government through two reportable segments—Defense and Intelligence, which provides services to the U.S. Department of Defense (DoD), intelligence community, branches of the U.S. Armed Forces, and other DoD agencies; and Civilian and Health Care, which provides services to the Departments of Homeland Security, Justice, and Health and Human Services, as well as other federal civilian and state and local government agencies. The following tables summarize reportable segment profit and reconciliation of reportable segment profit to income before taxes:


Selected Segment Measures (Unaudited)


Fiscal Quarter Ended


January 1, 2021


December 31, 2019

(in millions, except profit margin)


Defense and
Intelligence


Civilian and
Health Care


Total


Defense and
Intelligence


Civilian and
Health Care


Total

Revenue

$

795

$

339

$

1,134

$

813

$

313

$

1,126

Segment profit

$

105

$

43

$

148

$

115

$

39

$

154

Non-GAAP adjustments (a)

2

1

3

Adjusted segment profit (b)

$

105

$

43

$

148

$

117

$

40

$

157

Segment profit margin


13.2


%


12.7


%


13.1


%


14.1


%


12.5


%


13.7


%

Adjusted segment profit margin (b)


13.2


%


12.7


%


13.1


%


14.4


%


12.8


%


13.9


%

Notes:

(a)

Non-GAAP adjustments include non-operating net periodic pension benefit, and certain separation-related and other costs. Each of the individual items was immaterial for the fiscal quarters ended January 1, 2021 and December 31, 2019.

(b)

Adjusted results represent non-GAAP financial measures, and it should be considered in addition to, but not as substitute for, the information provided in accordance with GAAP.

 


Reconciliation of Reportable Segment Profit to Income Before Taxes (Unaudited)


Fiscal Quarter Ended

(in millions)


January 1, 2021


December 31, 2019

Total profit for reportable segments

$

148

$

154

Not allocated to segments:

Share-based compensation

(10)

(6)

Amortization of acquired intangible assets

(60)

(54)

Restructuring costs

(2)

Separation, transaction and integration-related costs

(7)

(20)

Interest expense, net

(28)

(34)

Other income and (expense), net

4

35

Income before taxes

$

45

$

75

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/perspecta-announces-financial-results-for-third-quarter-of-fiscal-year-2021-301223288.html

SOURCE Perspecta Inc.

Orbia Announces Conference Call for Its Fourth Quarter 2020 Earnings Results

Orbia Announces Conference Call for Its Fourth Quarter 2020 Earnings Results

MEXICO CITY–(BUSINESS WIRE)–
Orbia Advance Corporation, S.A.B. de C.V. will release its fourth quarter 2020 earnings results after the market closes on Wednesday, February 24th, 2021.

Management will host a conference call to review results from the quarter.

Date:

Thursday,

February 25th, 2021

Time:

10:00 am (Mexico City Time)

11:00 am (US Eastern Time)

Speakers:

Sameer Bharadwaj

Chief Executive Officer

Edgardo Carlos

Chief Financial Officer

Javier Luna

Capital Markets and

Investor Relations

Director

Number:

From the USA (toll free):

+1-(888)-339-0721

From Mexico (toll free):

+001-855-817-7630

From other countries:

+1-(412)-317-5247

REGISTER HERE

  • When dialing in, please let the operator know you are here for the Orbia earnings call.
  • Participants are requested to connect 10 minutes prior to start time.
  • The presentation that will be used during the webcast will be available on the Investors section of the Orbia website. A recording of the webcast will be posted on the website shortly after the call is completed. The webcast can be accessed here. 

 

Investors

Javier Luna, Capital Markets and Investor Relations Director

+52 55 5366 4151

[email protected]

KEYWORDS: New York Mexico United States Central America North America

INDUSTRY KEYWORDS: Technology Manufacturing Construction & Property Other Transport Mining/Minerals Building Systems Transport Agriculture Natural Resources Telecommunications Chemicals/Plastics

MEDIA:

Logo
Logo

Lake Shore Bancorp, Inc. Announces Fourth Quarter 2020 Dividend

DUNKIRK, N.Y., Feb. 05, 2021 (GLOBE NEWSWIRE) — Lake Shore Bancorp, Inc. (the “Company”) (NASDAQ Global Market: LSBK), the holding company for Lake Shore Savings Bank (the “Bank”), announced that the Company’s Board of Directors approved a $0.13 per share cash dividend on its common stock, payable on March 15, 2021, to shareholders of record as of February 26, 2021. Based on the Company’s closing stock price of $13.50 on February 3, 2021, the implied dividend yield for the Company’s common stock is currently 3.85%.

On February 3, 2021, Lake Shore, MHC (the “MHC”), which holds 3,636,875 shares, or 62.5% of the Company’s total outstanding common stock, held a special meeting of its members (the members are depositors of Lake Shore Savings Bank). During this special meeting, the members approved a proposal for the MHC to waive its right to receive dividends declared by the Company on its common stock (up to an aggregated amount of $0.54 per share) during the next 12 months. More than 55% of the votes eligible were cast. Of the votes cast, 96.5% were in favor of the proposal.

Following the receipt of member approval, the MHC will apply to the Federal Reserve Board for its non-objection to dividend waivers by the MHC for the next 12 months. If this non-objection is obtained from the Federal Reserve Board prior to March 15, 2021, the expected dividend payment date, the MHC intends to waive its receipt of the dividend.

“We appreciate the annual efforts of our members to vote for the MHC dividend waiver,” stated Daniel P. Reininga, President and CEO. “This vote allows us to preserve capital at the mid-tier holding company and at the Bank so that we can leverage our resources to support the banking needs of our customers and communities.”

Company Profile

Lake Shore Bancorp, Inc. (NASDAQ Global Market: LSBK) is the mid-tier holding company of Lake Shore Savings Bank, a federally chartered, community-oriented financial institution headquartered in Dunkirk, New York. The Bank has eleven full-service branch locations in Western New York, with five locations in Chautauqua County, New York and six locations in Erie County, New York. The Company had total assets of $682.2 million and total deposits of $560.3 million as of December 31, 2020. The Bank offers a broad range of retail and commercial lending and deposit services. The Company’s common stock is traded on the NASDAQ Global Market as “LSBK”. Additional information about the Company is available at www.lakeshoresavings.com.


Safe-Harbor


This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, that are based on current expectations, estimates and projections about the Company’s and the Bank’s industry, and management’s beliefs and assumptions. Words such as anticipates, expects, intends, plans, believes, estimates and variations of such words and expressions are intended to identify forward-looking statements. Such statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to forecast. Therefore, actual results may differ materially from those expressed or forecast in such forward-looking statements. The Company and Bank undertake no obligation to update publicly any forward-looking statements, whether as a result of new information or otherwise.


Investor/Media Contact

Rachel A. Foley
Chief Financial Officer
Lake Shore Bancorp, Inc.
31 East Fourth Street
Dunkirk, New York 14048
(716) 366-4070 ext. 1020



Horizons ETFs Announces Changes to Risk Ratings for Certain ETFs

Canada NewsWire

TORONTO, Feb. 5, 2021 /CNW/ – Horizons ETFs Management (Canada) Inc. (“Horizons ETFs“) today announced changes to the risk ratings applicable to three of its ETFs. The changes in risk ratings are effective immediately and detailed in the table below:


ETF


Ticker


Previous Risk
Rating


New Risk
Rating

Horizons Active Preferred Share ETF

HPR

Low to Medium

Medium

Horizons Active A.I. Global Equity ETF

MIND

Low to Medium

Medium

Horizons Active Floating Rate Preferred Share ETF

HFP

Low to Medium

Medium

These changes are the result of an annual review conducted in accordance with a standardized investment risk classification methodology, set out in National Instrument 81-102 Investment Funds, that is based on the historical volatility of the ETF as measured by the 10-year standard deviation of the returns of the ETF. If an ETF has less than 10 years of performance history, the investment risk level of the ETF is calculated using the return history of the ETF and, for the remainder of the 10 year period, the return history of a reference index that is expected to reasonably approximate the standard deviation of the ETF.

No changes have been made to the investment objectives or strategies of these ETFs as a result of the changes to the risk ratings. A summary of the risk rating classification methodology, investment objectives and strategies of an ETF can be found in the ETF’s most recently filed prospectus.

About Horizons ETFs Management (Canada) Inc. (www.HorizonsETFs.com)

Horizons ETFs Management (Canada) Inc. is an innovative financial services company and offers one of the largest suites of exchange traded funds in Canada. The Horizons ETFs product family includes a broadly diversified range of solutions for investors of all experience levels to meet their investment objectives in a variety of market conditions. Horizons ETFs has more than $17.5 billion of assets under management and 94 ETFs listed on major Canadian stock exchanges.

Horizons ETFs is a Member of Mirae Asset Global Investments. Commissions, management fees and expenses all may be associated with an investment in exchange traded products managed by Horizons ETFs Management (Canada) Inc. (the “Horizons Exchange Traded Products”). The Horizons Exchange Traded Products are not guaranteed, their values change frequently and past performance may not be repeated. The prospectus contains important detailed information about the Horizons Exchange Traded Products. Please read the relevant prospectus before investing.

SOURCE Horizons ETFs Management (Canada) Inc.

Pacific Biosciences Grants Equity Incentive Award to New Employee

MENLO PARK, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of Pacific Biosciences common stock and restricted stock units (“RSU”) covering 50,000 shares of Pacific Biosciences common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan on December 14, 2020 (the “2020 Inducement Plan”).

The 2020 Inducement Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of Pacific Biosciences as an inducement material to such individual’s entering into employment with Pacific Biosciences in accordance with Nasdaq Marketplace Rule 5635(c)(4).

The options have an exercise price of $ 34.18 per share, which is equal to the closing price of Pacific Biosciences common stock on February 1, 2021 (the “Effective Date”). The shares subject to the option shall be scheduled to vest and become exercisable as to 1/4th of the total number of shares subject at grant to the Option on the one (1) year anniversary of the Effective Date and as to 1/48th of the total shares subject at grant to the Option each month thereafter on the same day of the month as the Effective Date (or the last day of the month, if a particular month does not have a corresponding day). The RSUs shall be scheduled to vest as to 1/4th of the total number of shares subject at grant to the RSUs on each of the one (1), two (2), three (3), and four (4) year anniversaries of the Effective Date. The option grant and the award of restricted stock units are subject to the terms and conditions of the 2020 Inducement Plan and the award agreements entered into with the non-executive officer employee.

About Pacific Biosciences

Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing. The company’s innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism. Cited in thousands of peer-reviewed publications, PacBio® sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology.

Contact

Investors: Trevin Rard
650.521.8450
[email protected]



Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced grants of stock options to three new employees to purchase an aggregate of 38,000 shares of the Company’s common stock with an exercise price of $5.79 per share, the closing price of Assembly Bio’s common stock on February 1, 2021. The stock options were granted as material inducements to the new employees to accept the Company’s offers of employment.

The stock options have a ten-year term and vest over four years, with one-fourth vesting on the first anniversary of the date of grant and the remaining three-fourths vesting in approximately equal monthly installments. The stock options are, in all cases, subject to the new employees’ continued service with Assembly Bio through the applicable vesting dates and to acceleration upon the occurrence of certain events as set forth in the award agreements evidencing the stock options. None of the new employees are executive officers.

The stock options were granted outside of Assembly Bio’s stockholder-approved equity incentive plans pursuant to Assembly Bio’s 2020 Inducement Award Plan. The stock option awards were approved by the Compensation Committee of Assembly Bio’s Board of Directors, which is comprised solely of independent directors, as a material inducement to entering into employment with Assembly Bio in accordance with Nasdaq Listing Rule 5635(c)(4), which requires this public announcement.

About Assembly Biosciences

Assembly Biosciences, Inc. is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV). The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients.

For more information, visit assemblybio.com.

Contacts

Assembly Bio
Lauren Glaser
Senior Vice President, Investor Relations and Corporate Affairs
(415) 521-3828
[email protected]



ETC Announces Notice of Annual Meeting of Shareholders

SOUTHAMPTON, Pa., Feb. 05, 2021 (GLOBE NEWSWIRE) — Environmental Tectonics Corporation (OTC Pink: ETCC) (“ETC” or the “Company”) today announces that the Annual Meeting of the Shareholders (“Annual Meeting”) will be held live via the Internet on March 10, 2021 at 10:00 a.m.

The Board of Directors has fixed the close of business on December 23, 2020 as the Record Date for the determination of shareholders entitled to notice of and to vote at the Annual Meeting. The proxy materials, which provide information about ETC and describe the business we will conduct at the Annual Meeting, were made available on or about February 1, 2021 to ETC shareholders as of the Record Date.

If you are unable to attend the Annual Meeting, it is still important that your shares be represented. Please vote your shares promptly.

ETC is headquartered in Southampton, PA. For more information about ETC, visit http://www.etcusa.com/.


Forward-looking Statements

This news release contains forward-looking statements, which are based on management’s expectations and are subject to uncertainties and changes in circumstances. Words and expressions reflecting something other than historical fact are intended to identify forward-looking statements, and these statements may include words such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “future”, “predict”, “potential”, “intend”, or “continue”, and similar expressions. We base our forward-looking statements on our current expectations and projections about future events or future financial performance. Our forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about ETC and its subsidiaries that may cause actual results to be materially different from any future results implied by these forward-looking statements. We caution you not to place undue reliance on these forward-looking statements.

Contact:   Mark Prudenti, CFO
     
Phone:   (215) 355-9100 x1531
     
E-mail:   [email protected]



Allegion’s Board Increases Quarterly Dividend by 13%

Allegion’s Board Increases Quarterly Dividend by 13%

DUBLIN–(BUSINESS WIRE)–Allegion plc (NYSE: ALLE), a leading global provider of security products and solutions, today announced that its board of directors declared a quarterly dividend of $0.36 per ordinary share of the company – representing a 13-percent increase from 2020 and the company’s seventh consecutive year of annual increase in dividends.

“Allegion remains committed to driving shareholder value, and our board supports our plan to return cash to shareholders with an annual rate of dividend increase above our annual earnings growth rate,” said David D. Petratis, Allegion chairman, president and CEO. “This latest dividend increase conveys our confidence in the company’s efficient cash flow generation. It also demonstrates the continued execution of a flexible and balanced capital allocation strategy.”

The dividend is payable on March 31, 2021, to shareholders of record on March 17, 2021.

About Allegion

Allegion (NYSE: ALLE) is a global pioneer in seamless access, with leading brands like CISA®, Interflex®, LCN®, Schlage®, SimonsVoss® and Von Duprin®. Focusing on security around the door and adjacent areas, Allegion secures people and assets with a range of solutions for homes, businesses, schools and institutions. Allegion had $2.9 billion in revenue in 2019 and sells products in almost 130 countries.

For more, visit www.allegion.com.

Media Contact:

Whitney Moorman – Reputation Management Leader

317-810-3241

[email protected]

Analyst Contact:

Tom Martineau – Vice President, Investor Relations, and Treasurer

317-810-3759

[email protected]

KEYWORDS: North America United States Ireland United Kingdom Europe Indiana

INDUSTRY KEYWORDS: Technology Professional Services Interior Design Home Goods Architecture Residential Building & Real Estate Commercial Building & Real Estate Other Manufacturing Construction & Property Security Manufacturing Building Systems Retail Hardware Finance Office Products Consumer Electronics

MEDIA:

Logo
Logo